达格列净治疗2型糖尿病有效性及安全性的Meta分析

发布时间：2018-06-05 10:43

  本文选题：达格列净 + 钠-葡萄糖其转运蛋白抑制剂　； 参考：《沈阳药科大学学报》2017年10期

【摘要】：目的系统评价钠-葡萄糖共转运蛋白2(sodium-dependent glucose transporter 2,SGLT-2)抑制剂达格列净治疗2型糖尿病(type 2 diabetes,T2DM)患者的有效性和安全性。方法计算机检索Pub Med、The Cochrane Library、EMbase、中国知网和万方数据库,检索时限截止至2016年3月,由两名研究者分别对纳入文献进行数据提取与质量评价后,采用Rev Man 5.3和Stata12.0软件进行Meta分析。结果纳入19个随机对照试验,共8 618例患者。Meta分析结果显示,与安慰剂相比,达格列净组患者糖化血红蛋白(hemoglobin A1c,Hb A1c)水平降低[WMD=-0.49,95%CI(-0.65,-0.34),P0.001];体重减轻[(WMD=-1.84 kg,95%CI(-2.09,-1.59),P0.001];收缩压[WMD=-3.07,95%CI(-3.92,-2.23),P0.001]和舒张压[WMD=-1.66,95%CI(-2.30,-1.01),P0.001]均有所下降,总不良反应发生率比较差异无统计学意义[RR=1.10,95%CI(0.99,1.22),P=0.09];低血糖发生率比较差异无统计学意义[RR=1.10,95%CI(0.99,1.24),P=0.09];泌尿系感染发生率比较差异无统计学意义[RR=1.09,95%CI(0.92,1.29),P=0.34];肾功能损伤发生率[RR=1.78,95%CI(1.04,3.05),P=0.03]以及生殖系感染发生率[RR=3.27,95%CI(2.39,4.47),P0.001]均增高。结论达格列净虽增加生殖系感染发生率及肾功能损伤发生率,但能有效降低T2DM患者Hb A1c水平、体重和血压,影响血脂水平,不良反应发生率、低血糖发生率和泌尿系感染的发生率与安慰剂相当。
[Abstract]:Objective to evaluate the efficacy and safety of sodium glucose cotransporter (2(sodium-dependent glucose transporter 2) SGLT-2 inhibitor Daglitrine in the treatment of type 2 diabetes mellitus (T2DM). Methods the Cochrane Library EMbase, China knowledge Network and Wanfang database were searched by computer. The retrieval time was up to March 2016. After data extraction and quality evaluation were carried out by two researchers respectively, Meta-analysis was carried out by Rev Man 5.3 and Stata12.0 software. 缁撴灉绾冲叆19涓�闅忔満瀵圭収璇曢�，

本文编号：1981703